The Y deletion gr/gr and susceptibility to testicular germ cell tumor

被引:154
作者
Nathanson, KL
Kanetsky, PA
Hawes, R
Vaughn, DJ
Letrero, R
Tucker, K
Friedlander, M
Phillips, KA
Hogg, D
Jewett, MAS
Lohynska, R
Daugaard, G
Richard, S
Chompret, A
Bonäti-Pellié, C
Heidenreich, A
Olah, E
Geczi, L
Bodrogi, I
Ormiston, WJ
Daly, PA
Oosterhuis, JW
Gillis, AJM
Looijenga, LHJ
Guilford, P
Fosså, SD
Heimdal, K
Tjulandin, SA
Liubchenko, L
Stoll, H
Weber, W
Huddart, R
Crockford, GP
Forman, D
Oliver, DT
Einhorn, L
Weber, BL
Kramer, J
McMaster, M
Greene, MH
Pike, M
Cortessis, V
Chen, C
Schwartz, SM
Bishop, DT
Easton, DF
Stratton, MR
Rapley, EA
机构
[1] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA
[2] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA
[3] Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA
[4] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA
[5] Inst Canc Res, Sect Canc Genet, Sutton, Surrey, England
[6] Univ New S Wales, Dept Med Oncol, Div Med, Sydney, NSW, Australia
[7] Prince Wales Hosp Randwick, Sydney, NSW, Australia
[8] Peter MacCallum Canc Ctr, Dept Haematol & Med Oncol, Melbourne, Vic, Australia
[9] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[10] Univ Toronto, Toronto, ON, Canada
[11] Univ Hosp Prague, Dept Radiotherapy & Oncol, Prague, Czech Republic
[12] Rigshosp, Dept Oncol, DK-2100 Copenhagen, Denmark
[13] CHU Bicetre, EPHE, UMR 8125, Fac Med Paris Sud, Le Kremlin Bicetre, France
[14] CHU Bicetre, Serv Urol, Le Kremlin Bicetre, France
[15] Inst Gustave Roussy, Villejuif, France
[16] Hop Paul Brousse, INSERM U535, Villejuif, France
[17] Univ Marburg, Dept Urol Oncol, Marburg, Germany
[18] Natl Inst Oncol, Dept Mol Genet, Budapest, Hungary
[19] Natl Inst Oncol, Dept Chemotherapy, Budapest, Hungary
[20] St James Hosp, Dept Med Oncol, Dublin 8, Ireland
[21] Erasmus Univ, Med Ctr, Dept Pathol, Rotterdam, Netherlands
[22] Dr Daniel Den Hoed Canc Ctr, Josphine Nefkens Inst, NL-3008 AE Rotterdam, Netherlands
[23] Univ Otago, Canc Genet Lab, Dunedin, New Zealand
[24] Natl Hosp Norway, Radiumhosp Trust, Dept Clin Canc Res & Genet, Oslo, Norway
[25] NN Blokhin Russian Canc Res Ctr, Lab Clin Genet, Inst Clin Oncol, Moscow, Russia
[26] Univ Basel Hosp, Familial Canc Clin, CH-4031 Basel, Switzerland
[27] St James Univ Hosp, Genet Epidemiol Div, Canc Res UK Clin Ctr, Leeds, W Yorkshire, England
[28] Barts & London Queen Marys Sch Med & Dent, Dept Med Oncol, London, England
[29] Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46204 USA
[30] NCI, Clin Genet Branch, Div Canc Epidemiol & Genet, NIH, Rockville, MD USA
[31] Univ So Calif, Dept Preventat Med, Keck Sch Med, Los Angeles, CA USA
[32] Fred Hutchinson Canc Res Ctr, Program Epidemiol, Seattle, WA 98104 USA
[33] Univ Cambridge, Canc Res UK, Genet Epidemiol Unit, Cambridge, England
关键词
D O I
10.1086/498455
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Testicular germ cell tumor (TGCT) is the most common cancer in young men. Despite a considerable familial component to TGCT risk, no genetic change that confers increased risk has been substantiated to date. The human Y chromosome carries a number of genes specifically involved in male germ cell development, and deletion of the AZFc region at Yq11 is the most common known genetic cause of infertility. Recently, a 1.6-Mb deletion of the Y chromosome that removes part of the AZFc region-known as the "gr/gr" deletion-has been associated with infertility. In epidemiological studies, male infertility has shown an association with TGCT that is out of proportion with what can be explained by tumor effects. Thus, we hypothesized that the gr/gr deletion may be associated with TGCT. Using logistic modeling, we analyzed this deletion in a large series of TGCT cases with and without a family history of TGCT. The gr/gr deletion was present in 3.0% (13/431) of TGCT cases with a family history, 2% (28/1,376) of TGCT cases without a family history, and 1.3% (33/2,599) of unaffected males. Presence of the gr/gr deletion was associated with a twofold increased risk of TGCT (adjusted odds ratio [aOR] 2.1; 95% confidence interval [CI] 1.3-3.6; P = .005) and a threefold increased risk of TGCT among patients with a positive family history (aOR 3.2; 95% CI 1.5-6.7; P = .0027). The gr/gr deletion was more strongly associated with seminoma (aOR 3.0; 95% CI 1.6-5.4; P = .0004) than with nonseminoma TGCT (aOR 1.5; 95% CI 0.72-3.0; P = .29). These data indicate that the Y microdeletion gr/gr is a rare, low-penetrance allele that confers susceptibility to TGCT.
引用
收藏
页码:1034 / 1043
页数:10
相关论文
共 47 条
[1]   TESTICULAR CANCER IN 9 NORTHERN EUROPEAN COUNTRIES [J].
ADAMI, HO ;
BERGSTROM, R ;
MOHNER, M ;
ZATONSKI, W ;
STORM, H ;
EKBOM, A ;
TRETLI, S ;
TEPPO, L ;
ZIEGLER, H ;
RAHU, M ;
GUREVICIUS, R ;
STENGREVICS, A .
INTERNATIONAL JOURNAL OF CANCER, 1994, 59 (01) :33-38
[2]   Risk factor patterns for cryptorchidism and hypospadias [J].
Akre, O ;
Lipworth, L ;
Cnattingius, S ;
Sparén, P ;
Ekbom, A .
EPIDEMIOLOGY, 1999, 10 (04) :364-369
[3]   Increase in testicular cancer incidence in six European countries: A birth cohort phenomenon [J].
Bergstrom, R ;
Adami, HO ;
Mohner, M ;
Zatonski, W ;
Storm, H ;
Ekbom, A ;
Tretli, S ;
Teppo, L ;
Akre, O ;
Hakulinen, T .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (11) :727-733
[4]  
Bosl George J., 1997, P1397
[5]  
DAVIES JM, 1981, LANCET, V1, P928
[6]   High frequency of gr/gr chromosome Y deletions in consecutive oligospermic ICSI candidates [J].
de Llanos, M ;
Ballescà, JL ;
Gázquez, C ;
Margarit, E ;
Oliva, R .
HUMAN REPRODUCTION, 2005, 20 (01) :216-220
[7]   The CDY-related gene family:: coordinated evolution in copy number, expression profile and protein sequence [J].
Dorus, S ;
Gilbert, SL ;
Forster, ML ;
Barndt, RJ ;
Lahn, BT .
HUMAN MOLECULAR GENETICS, 2003, 12 (14) :1643-1650
[8]  
Ferlay J, 2004, GLOBOCAN 2002 CANC I
[9]   Association of partial AZFc region deletions with spermatogenic impairment and male infertility [J].
Ferlin, A ;
Tessari, A ;
Ganz, F ;
Marchina, E ;
Barlati, S ;
Garolla, A ;
Engl, B ;
Foresta, C .
JOURNAL OF MEDICAL GENETICS, 2005, 42 (03) :209-213
[10]   FAMILIAL TESTICULAR CANCER - A REPORT OF THE UK FAMILY REGISTER, ESTIMATION OF RISK AND AN HLA CLASS-1 SIB-PAIR ANALYSIS [J].
FORMAN, D ;
OLIVER, RTD ;
BRETT, AR ;
MARSH, SGE ;
MOSES, JH ;
BODMER, JG ;
CHILVERS, CED ;
PIKE, MC .
BRITISH JOURNAL OF CANCER, 1992, 65 (02) :255-262